| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
CONCORD, Mass.—Early December saw non-Hodgkin’s lymphoma (NHL) news from Alopexx Oncology LLC when it announced data from a Phase 1 trial of DI-Leu16-IL2, a recombinant antibody fusion protein (immunocytokine) composed of interleukin-2 and a CD20-targeting monoclonal antibody.
 
The CD20 antibody recognizes the same target on B cells as Rituxan and maintains the activities of both the antibody and cytokine components, but is also involved in tumor targeting, engagement of the immune system and induction of an anticancer vaccine effect. The results of the study were presented at the 58th annual American Society of Hematology (ASH) meeting in San Diego.
 
Twenty-two patients with relapsed or refractory B-cell CD20-positive lymphoma, in five dose cohorts, have been enrolled. Fifteen of 18 patients receiving two or more cycles of therapy had tumor regression or stabilization including three complete and two partial responses. The durations of response were over 12 months in many cases. The durability of those responses was maintained in patients months after stopping treatment, suggesting a vaccine effect had occurred. These study results are similar to a previous investigator-sponsored Phase 1 study conducted at the City of Hope by Dr. Andrew Raubitschek.
 
Overall, DI-Leu16-IL2 was well tolerated as outpatient therapy. Unlike normal IL-2 treatment, the most common toxicities encountered were a mild skin rash that resolved spontaneously. Subcutaneous dosing was employed in the study to deliver the drug directly into the lymphatic system, allowing for higher dosing and lower side effects than with IV infusion. In addition, the effective dose of DI-Leu16-IL2 was 100-200-fold lower than Rituxan. This suggests that by targeting the tumor microenvironment, an effective treatment can occur at a much lower dose and opens the door to future combination therapy with established drugs like immune checkpoint inhibitors.
 
“The findings to date are very encouraging and support our belief that DI-Leu16-IL2 has the potential to become an effective therapy in the treatment of refractory NHL either alone or in combination,” said Dr. Daniel Vlock, founder and CEO of Alopexx Enterprises.
 
CD20 is a protein frequently expressed on cancer cells associated with NHL. Preclinical studies have shown that DI-Leu16-IL2, which has activities of both the anti-CD20 antibody and cytokine components, targets the tumor cells, engages the immune system and has the potential to produce an anti-cancer vaccine effect. As a result of this vaccine-like effect, long-term anticancer activity should continue and future cancer cells could be destroyed even without the need for re-dosing.
 
“The fusion of the anti-CD20 antibody and the cytokine IL2 creates an effect that is far more powerful than administering those therapeutics individually or in combination,” explained Dr. Stephen Gillies, chief scientific officer of Alopexx Oncology. “In this therapeutic approach, the drug elicits a T cell response and also activates the innate immunity to kill tumor cells, and that is a very important distinction between this and other treatments.”

Related Topics

Published In

Volume 13 - Issue 1 | January 2017

January 2017

January 2017 Issue

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Laboratorian with a white coat and blue gloves pipettes green liquid into a beaker with multicolored liquids in beakers and tubes in the blue-tinged, sterile laboratory background.

Discovering cutting-edge nitrosamine analysis in pharmaceuticals

New tools help researchers detect and manage harmful nitrosamine impurities in drugs such as monoclonal antibodies.
A starry night sky reflected over calm water, symbolizing the discovery of hidden patterns in complex systems.

Technology Guide: Spatial biology techniques

Discover essential strategies and expert insights to navigate the expanding world of spatial biology.
Red tumor cells are shown against a teal backdrop showing attachment to tissue.

Decoding the tumor microenvironment with immune profiling

Integrating multiplexed immunohistochemistry with spatial analysis offers a practical way to uncover tumor-immune dynamics.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue